Hyundai ADM Announces Breakthrough in Cancer Metastasis Research with ‘Penitrium’
A novel approach to combating cancer has emerged from Hyundai ADM, with researchers announcing the first-ever identification of a multi-targeting effect that simultaneously preemptively blocks three key factors driving cancer cell metastasis. This groundbreaking achievement, demonstrated in a pancreatic cancer patient-derived organoid (PDO) model, promises a new paradigm in cancer treatment, moving beyond simply attacking cancer cells to disrupting their ability to spread.
Solving a 137-Year-Old Puzzle: The ‘Seed and Soil’ Hypothesis
The research, a collaborative effort between Hyundai ADM, C&Pharm, and Hyundai Bioscience – collectively known as the ‘Project 2023 Global AI-IP Bio New Drug Team’ – presents a clinical solution to the “Seed and Soil” hypothesis. Proposed by Stephen Paget in 1889, this long-standing theory posits that cancer metastasis isn’t solely determined by the cancer cells themselves (“seeds”), but also by the environment they land in (“soil”). For over a century, understanding and manipulating this interplay has remained a significant challenge in oncology.
According to a company release, the team’s findings represent a departure from existing anticancer drugs, which primarily focus on eliminating cancer cells directly. Instead, this new strategy focuses on controlling the microenvironment in which cancer cells grow, effectively preventing them from establishing new tumors. The research was conducted in partnership with Organoid Science, specializing in organoid culture and drug processing, and Gencurix, a company focused on cancer molecular diagnostics.
‘Penitrium’ Establishes a ‘Three Lines of Defense’ Against Metastasis
The core of this breakthrough lies in a candidate material called Penitrium. Joint research demonstrated that Penitrium creates a hostile environment for cancer cells, establishing a comprehensive “three lines of defense” against the entire metastatic process.
These defenses work in concert:
- Inhibition of Niche Formation: The research team confirmed that Penitrium suppresses remodeling of the extracellular matrix (ECM), the physical scaffolding that supports metastasis. Reduced expression of genes like collagen (COL1A1) and fibronectin (FN1) disrupts the “surrounding environment,” mechanically hindering cancer cell engraftment.
- Induction of Anoikis: Penitrium inhibits the adhesion proteins Integrin and CD44, which enable cancer cells to attach to tissues. Without these anchors, cancer cells undergo anoikis – a process of self-destruction triggered by detachment from their surroundings – effectively eliminating them as they circulate in the bloodstream.
- Inhibition of Mitochondrial Energy Metabolism: The team also found that Penitrium disrupts oxidative phosphorylation (OXPHOS), the process by which mitochondria generate energy. By cutting off this vital energy supply, Penitrium induces a state of “metabolic starvation” in cancer cells, crippling their ability to metastasize.
Clinical Trials to Begin for Late-Stage Cancers
Based on these promising preclinical results, Hyundai ADM plans to initiate phase 1 clinical trials for a combination immunotherapy approach targeting patients with late-stage breast and lung cancer. The focus of these trials, according to the company, is not simply extending life expectancy, but eliminating the direct causes of cancer-related mortality.
“Worldwide, 10 million people die from cancer every year, and more than 9 million, or 90% of them, die due to metastasis,” stated Cho Won-dong, CEO of Hyundai ADM. “By creating a ‘surrounding environment’ in which cancer cells traveling through the bloodstream can never grow, we have presented the world’s first solution to ‘Seed and Soil,’ which has been a difficult problem for 137 years. This clinical trial will be a historic turning point in humanity escaping death from cancer by breaking down the basis for cancer cell engraftment and blocking metastasis at the source through the combined use of penetrium and anti-cancer immunotherapy.”
This research represents a significant step forward in the fight against cancer, offering a potentially transformative approach to preventing the spread of this devastating disease.
